Ascentage Pharma Announces 2023 Annual Results : vimarsana.com

SUZHOU, China and ROCKVILLE, Md., March 27, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its annual results for the full year 2023. During the reporting period, Ascentage Pharma made further strides in revenue generation through its commercialized product, achieved...

Related Keywords

China , Australia , Suzhou , Jiangsu , Canada , Philadelphia , Pennsylvania , United States , Rockville , American , Ascentage Phara , Prnewswire Ascentage Pharma , Ascentage Pharma , Dajun Yang , Drug Administration , Global Manufacturing Center , National Reimbursement Drug List , National Comprehensive Cancer Network , American Society Of Clinical Oncology Annual Meeting , European Union , China National Medical Products Administration , American Society Of Hematology , Model Product , China Developed Innovative Drugs , Reimbursement Drug List , Drug Evaluation , American Society , Oral Presentations , Oral Presentation , Oral Report , Clinical Oncology Annual Meeting , Breakthrough Therapy Designation , Good Manufacturing Practice , Qualified Person ,